31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Ozempic goes generic as Novo’s key patent expires

20 March 2026 As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.

Americas

Masimo convinces judge that Apple took secrets—but it’s not enough

19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

More features

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Arnold & Porter adds tech litigator in San Francisco

To cite or not to cite: How can we avoid misuse of AI in court?

Emotional Perception: What next for patent holders?

Nine-partner litigation team leaves Winston & Strawn

Firm adds seven-lawyer team in second major merger

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Final call: Who are the world’s best in-house counsel?

Copyright compliance in the life sciences industry

More on this story

Editor's picks

Editor's picks

More features